Abstract The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet
aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived …

Agents that react with the platelet glycoprotein (GP) IIb/IIIa complex (αIIb/β3 integrin) to block
fibrinogen binding and platelet-platelet aggregation have been proved to be effective in …

The management of patients with coronary artery stents during the perioperative period is
one of the most important patient safety issues clinicians confront. Perioperative stent …

Platelet aggregation is not only an essential part of hemostasis, but also initiates acute
coronary syndrome or ischemic stroke. The precise understanding of the activation …

Abstract Glycoprotein (GP) IIb/IIIa receptor antagonists compose a subcategory of
antiplatelet medications that reduce thrombus formation through the blockade of key binding …

Thrombocytopenia, often severe, occurs in 1% to 2% of patients given the fibrinogen
receptor antagonist abciximab, a chimeric Fab fragment containing murine specificity …

Inhibitors of the platelet glycoprotein (GP) IIb-IIIa receptor (integrin α IIb β 3) reduce acute
thrombotic events in patients with coronary artery disease. To characterize the mechanism of …

ContextThrombus formation on disrupted atherosclerotic plaque is the major cause of acute
coronary events. Platelet inhibitors are the mainstay of drug therapy to reduce cardiac …

Snake venom disintegrins are the natural products that have been investigated as potent
inhibitors of various integrins. Functionally, disintegrins can be divided into three groups …

Platelets play a crucial role in the pathogenesis of stroke and antiplatelet agents exist for its
treatment and prevention. Through the use of LC-MS based protein expression profiling …